The approaching end of another decade prompted this short review of peptide drugs that successfully reached the European market from 2010 to the present. The article also gives a comparison of numbers of marketing authorisations granted to peptide drugs in Europe and the US over the last two decades as well as a glimpse of trends in the evolution of peptide drug development.
For more please download PDF file.
Contributed by Susan J. Tzotzos
Susan Tzotzos works for the Vienna-based biotech company Apeptico Forschung & Entwicklung GmbH, where she designs therapeutic peptides, oversees their synthesis and follows up their application in clinical trials. Susan also manages various research collaborations with university departments carrying out projects investigating the mode of action of Apeptico’s therapeutic peptides.